The rapid rise of GLP-1 treatments such as Ozempic, Mounjaro and the newly approved Wegovy pill is set to transform the UK food landscape, but new consumer data shows the commercial opportunity lies in mainstream health positioning, not medical branding.
PWC predicts that GLP-1 use in the UK is expected to double following the approval of the Wegovy pill, which removes a major barrier to adoption by shifting treatment into a more accessible, less medicalised format.
Against this backdrop, new data from product intelligence business, Vypr, shows that 11% of UK adults are already current or former GLP-1 users, and their nutritional needs are shifting dramatically. Appetite reduction, taste changes and digestive sensitivity are driving users toward higher-protein, nutrient-dense, smaller-portion foods. These are needs that align closely with broader health trends already reshaping UK grocery.
Despite the growing user base, explicit GLP-1 branding remains a commercial risk. Only 16% of non-users say they would consider buying a product labelled as “GLP-1-friendly”, even if it supported weight management. A further 42% are neutral, signalling indifference rather than rejection.
High-protein ready meals, nutrient-dense snack bars, portion-controlled meal kits and gentler-textured products can all serve GLP-1 users while appealing to the wider health-conscious market.
The recent Consumer Horizon Report from Vypr highlights a significant credibility challenge as 54% of UK adults distrust generic GLP-1 treatments, with distrust rising sharply among consumers over 65. While 25-34-year-olds are the most trusting age group, 39% still express distrust. Any food brand that leans too heavily into GLP-1 terminology risks inheriting this scepticism.
However, among GLP-1 users themselves, demand for food specifically for their needs is strong. 70% said they would be more likely to buy food created especially for GLP-1 users. Nearly two-thirds (65%) would pay a premium for the products (mostly around 10% higher) and those aged 25-34 have the highest willingness to spend and the strongest trust in GLP-1-adjacent products.
Sentiment toward GLP-1 treatments is notably polarised: 35% of responses were positive (citing weight loss, reduced cravings and improved health markers) while 51% were negative (nausea, digestive issues, fatigue and taste distortion). This is a user base experiencing genuine physiological change, who have seen their habits drastically realigned.
Ben Davies, founder of Vypr, said: “GLP-1 users’ needs for high protein, nutrient density, clean ingredients and smaller portions are already driving mainstream category innovation. Marks & Spencer is leading the way with its range of healthy meals to appeal to this audience which will grow massively as more people take up the weight loss medication.
“GLP-1 is emerging as a category-shaping force in UK grocery. Brands don’t need to badge products as GLP-1-friendly. They just need to formulate smartly to take advantage of this growing customer base.”
